important annc, page-16

re: delayed reaction by market Hey Olenga , I must have missed the FDA approval when Novogen went to 8.70 with a market cap of over $800,000,000 on the hope of an objective response in their phase two . An increase $6 over their first phase 2 trials . I am not saying it will not turn out to be a great treatment , but no objective response that I saw to date . That is the biggest , but I can give you plenty of examples if you like . "we all know the drug works fairly well" Was some quote . You could have said we all know the drug has now been clinicaly proven to be more effective than any other Australian cancer drug to date , and probably would have been more accurate . Just remember the tumour reductions were in the first half of the very first phase 1 trial .